Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PPP5C | P53041 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.40 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.40 |
| ▸ | NPY4R | P50391 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12443549 | 0.80 | TFPI2 (0.65) | RECQLHPGDUSP2SMN1; SMN2GPR119 | |
| SCHEMBL9880147 | 0.80 | TFPI2 (0.65) | RECQLHPGDUSP2SMN1; SMN2GPR119 | |
| SCHEMBL9880141 | 0.76 | TFPI2 (0.56) | HPGDPPP5CPPP2CATFPI2NPY4R | |
| SCHEMBL14135612 | 0.75 | TFPI2 (0.46) | USP2MEN1KMT2APPP5CPPP2CA | |
| SCHEMBL16451149 | 0.74 | PPM1B (0.45) | MEN1KMT2APPP5CPPP2CATFPI2 | |
| SCHEMBL9880144 | 0.74 | TFPI2 (0.45) | PPP5CPPP2CATFPI2NPY4R | |
| SCHEMBL698803 | 0.72 | USP2 (0.69) | RECQLHPGDUSP2SMN1; SMN2GPR119 | |
| SCHEMBL18294 | 0.72 | USP2 (0.69) | RECQLHPGDUSP2SMN1; SMN2GPR119 | |
| SCHEMBL16612394 | 0.70 | USP2 (0.62) | RECQLHPGDUSP2SMN1; SMN2MEN1 | |
| SCHEMBL31706062 | 0.70 | HPGD (0.76) | RECQLHPGDUSP2SMN1; SMN2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210275521-A1 | OXABICYCLOHEPTANES FOR TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIA | LIXTE BIOTECHNOLOGY, INC. | 2021-09-09 | — | — | US | disclosed |
| EP-3258930-B1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DEPRESSIVE AND STRESS DISORDERS | LIXTE BIOTECHNOLOGY INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200179375-A1 | FORMULATIONS OF OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES | LIXTE BIOTECHNOLOGY, INC. | 2020-06-11 | — | — | US | disclosed |
| US-10668062-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes | LIXTE BIOTECHNOLOGY, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10434100-B2 | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-10413541-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10399993-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| WO-2019113155-A1 | OXABICYCLOHEPTANES FOR TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIA | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20190167671-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | LIXTE BIOTECHNOLOGY, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190046525-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-02-14 | — | — | US | disclosed |
| US-8058268-B2 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058268-B2 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-7998957-B2 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998957-B2 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| WO-2010014220-A1 | NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | LIXTE BIOTECHNOLOGY, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| WO-2008097561-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHOLOGY HOLDINGS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | SNCA, NLN, HTT | RECQL 145/4885HPGD 2500/4885USP2 2350/4885 |
| US-20200179375-A1 | FORMULATIONS OF OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES | PPP2CA, PPP2R2A, PPM1A | RECQL 3130/4885HPGD 2574/4885USP2 183/4885 |
| US-10413541-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | HSD17B11, HSD17B1, CRH | RECQL 1796/4885HPGD 180/4885USP2 1670/4885 |
| US-20190167671-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | PPP2CA, PPP3CA, PPP6C | RECQL 3804/4885HPGD 2615/4885USP2 544/4885 |
| US-20190046525-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | PPP2CA, PPP2R2A, PPM1A | RECQL 1249/4885HPGD 2016/4885USP2 86/4885 |
| US-20210275521-A1 | OXABICYCLOHEPTANES FOR TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIA | MCL1, MYD88, SAMHD1 | RECQL 2806/4885HPGD 666/4885USP2 2107/4885 |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | HCCS, VHL, OXA1L | RECQL 1995/4885HPGD 416/4885USP2 2402/4885 |
| US-10399993-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | RECQL 1565/4885HPGD 293/4885USP2 2933/4885 |
| US-10434100-B2 | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes | PPP2CA, PPP2R2A, PPM1A | RECQL 1249/4885HPGD 2016/4885USP2 86/4885 |
| US-10668062-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes | PPP2CA, PPP3CA, PPP6C | RECQL 3804/4885HPGD 2615/4885USP2 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.